All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @breannekallonen on TikTok · 40s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @breannekallonen's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00This is something that I actually see quite commonly in my practice.
  2. 0:04So I see a lot of individuals with hair loss and androgens.
  3. 0:08High levels of testosterone, DHE definitely can cause hair loss.
  4. 0:11And for some women, this is because their bodies are producing more of these androgens,
  5. 0:15but for others, I see it due to HRT.
  6. 0:19So overdoing testosterone replacement therapy absolutely has side effects such as hair loss
  7. 0:23and women see it to be very cautious.
  8. 0:25I'm not a big fan of super physiological dosaging.
  9. 0:29This often occurs with injections or pellets, so you do have to be very cautious.
  10. 0:33Testosterone is an important hormone for women.
  11. 0:35I absolutely agree.
  12. 0:36I think it's wonderful that you have to use the correct dose.

@breannekallonen's testosterone advice for women, fact-checked

Dr Breanne Kallonen ND

TikTok creator

12.5K viewsWatch on TikTok

Quick answer

Exogenous testosterone in women, particularly via pellets or injections, can produce supraphysiological androgen levels that trigger or worsen androgenic alopecia through DHT-mediated follicular miniaturization. The creator's clinical observation aligns with published case series and reviews documenting this as a recognized adverse effect of poorly titrated testosterone therapy in women. Individual variation in 5-alpha reductase activity and androgen receptor sensitivity means that hair loss risk cannot be assessed by serum testosterone levels alone.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @breannekallonen's testosterone advice for women, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@breannekallonen's testosterone advice for women, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@breannekallonen's testosterone advice for women, fact-checked" from Dr Breanne Kallonen ND. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Exogenous testosterone in women, particularly via pellets or injections, can produce supraphysiological androgen levels that trigger or worsen androgenic alopecia through DHT-mediated follicular miniaturization.

The reason this review is not generic is the source wording and the canonical claim label "trt replying to ashley i m not a big fan of high dosing of test." In this clip, the useful excerpt is: "This is something that I actually see quite commonly in my practice." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Glaser and Dimitrakakis (2013, Maturitas) documented supraphysiological testosterone levels and androgenic side effects including hair changes specifically in women using pellets.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Exogenous testosterone in women, particularly via pellets or injections, can produce supraphysiological androgen levels that trigger or worsen androgenic alopecia through DHT-mediated follicular miniaturization.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Exogenous testosterone in women, particularly via pellets or injections, can produce supraphysiological androgen levels that trigger or worsen androgenic alopecia through DHT-mediated follicular miniaturization. The creator's clinical observation aligns with published case series and reviews documenting this as a recognized adverse effect of poorly titrated testosterone therapy in women. Individual variation in 5-alpha reductase activity and androgen receptor sensitivity means that hair loss risk cannot be assessed by serum testosterone levels alone.
  • DHT, converted from testosterone by 5-alpha reductase in hair follicles, is the primary driver of androgen-induced hair miniaturization in women, not testosterone acting directly.
  • Glaser and Dimitrakakis (2013, Maturitas) documented supraphysiological testosterone levels and androgenic side effects including hair changes specifically in women using pellets.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • DHT, converted from testosterone by 5-alpha reductase in hair follicles, is the primary driver of androgen-induced hair miniaturization in women, not testosterone acting directly.
  • Glaser and Dimitrakakis (2013, Maturitas) documented supraphysiological testosterone levels and androgenic side effects including hair changes specifically in women using pellets.
  • Pellet implants cannot be removed if levels go too high, making them riskier than gels or patches for women prone to androgenic hair loss.
  • Female testosterone reference ranges vary significantly between labs and are not well standardized, so a result listed as 'normal' does not guarantee it is appropriate for that individual.
  • Hair shedding typically lags a hormonal trigger by 2 to 4 months, meaning you may not connect the dots between a dose change and hair loss without careful timeline tracking.
  • Islam et al. (2019, Journal of the American Academy of Dermatology) confirmed exogenous androgen exposure as a recognized cause of female pattern hair loss, validating the creator's core clinical point.
  • A proper workup for hair loss in women on HRT should include total testosterone, free testosterone, DHEA-S, DHT, thyroid function, and ferritin, since multiple deficiencies can mimic or compound androgen-related alopecia.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @breannekallonen actually say?

The creator, who appears to be a clinician, says she sees hair loss regularly in her practice tied to high androgen levels. Her core claim: "overdoing testosterone replacement therapy absolutely has side effects such as hair loss" in women. She singles out injections and pellets as the delivery methods most likely to push levels too high, and argues that "super physiological dosaging" is the problem, not testosterone itself.

She is careful to frame testosterone as genuinely useful for women, saying she thinks it is "wonderful" when used at the correct dose. This is a clinically responsible framing, even if the video is short on specifics about what "correct" actually means in practice.

Does the science back this up?

Mostly, yes. The androgen-hair loss connection in women is real and reasonably well-established, though the mechanism is more complicated than the video implies.

Androgen-induced hair loss in women typically involves dihydrotestosterone (DHT), which is converted from testosterone by the enzyme 5-alpha reductase in hair follicles. Follicles sensitive to DHT undergo miniaturization, producing progressively thinner strands. Glaser and Dimitrakakis (2013, Maturitas) documented supraphysiological testosterone levels in women using pellets and noted androgenic side effects including hair changes. A 2019 review by Islam et al. in the Journal of the American Academy of Dermatology confirmed that exogenous androgen exposure is a recognized cause of female pattern hair loss and hyperandrogenism-related alopecia.

The creator also mentions DHEA alongside testosterone. That is accurate. DHEA converts peripherally to both testosterone and estrogen, and elevated DHEA-S is associated with androgenic alopecia in women (Carmina et al., 2006, Fertility and Sterility).

Where the video is thin: it does not explain that individual sensitivity to androgens varies enormously. Some women lose hair at testosterone levels that are technically within range. Serum levels alone do not tell the whole story.

What did they get wrong (or right)?

She got the headline right. High-dose exogenous testosterone can cause hair loss in women, and pellets and injections are genuinely harder to titrate than gels or patches. That part is accurate.

What she glosses over is that hair loss from androgens in women is not purely a dose problem. It is also a sensitivity problem. Women with higher 5-alpha reductase activity or more androgen-sensitive follicles can experience alopecia even at normal testosterone levels. A clinician treating women for hair loss under HRT needs to think about both the dose and the individual's receptor sensitivity, not just whether the number on the lab report looks physiological.

She also mentions "DHE," which appears to be a shorthand for DHEA. The transcript is ambiguous here. If she meant DHT, that would be more precisely correct in the context of hair follicle physiology. If she meant DHEA, the point still holds but the mechanism is one step removed. This is a minor slip in language, not a factual error, but precision matters in clinical communication.

She is right to be skeptical of pellets for this specific concern. Pellet dosing is difficult to reverse if levels go too high, and the literature supports her caution (Glaser et al., 2013, Maturitas).

What should you actually know?

If you are a woman on testosterone therapy and noticing hair thinning, a few things are worth understanding before you panic or quit your prescription.

  • Hair shedding can lag behind a hormone change by two to four months, so timing matters when you try to connect cause and effect.
  • Not all hair loss on HRT is androgen-driven. Thyroid dysfunction, iron deficiency, and telogen effluvium from stress are common confounders that get missed when the assumption is always "too much testosterone."
  • DHT, not testosterone directly, is typically the proximate cause of follicle miniaturization. Some clinicians check DHT levels specifically rather than relying on total testosterone alone.
  • Delivery method matters. Gels and patches allow for finer dose adjustments and can be stopped quickly. Pellets cannot be removed easily and can leave levels elevated for months.
  • "Staying within normal ranges" is a reasonable starting principle, but female testosterone reference ranges are broad and poorly standardized across labs. A result in range does not automatically mean it is the right level for that individual.

If hair loss is a concern, the conversation with your prescriber should include a full androgen panel (total testosterone, free testosterone, DHEA-S, DHT), a thyroid panel, ferritin, and a scalp assessment, not just a single testosterone number.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr Breanne Kallonen ND · TikTok creator

12.5K views on this video

Replying to @Ashley I’m not a big fan of high dosing of testosterone in women. Ideally you want to stay within the normal ranges. Testosterone is important for women but if over done can cause hair lo

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about dht, converted from testosterone by 5-alpha reductase in hair follicles,?

DHT, converted from testosterone by 5-alpha reductase in hair follicles, is the primary driver of androgen-induced hair miniaturization in women, not testosterone acting directly.

What does the video say about glaser?

Glaser and Dimitrakakis (2013, Maturitas) documented supraphysiological testosterone levels and androgenic side effects including hair changes specifically in women using pellets.

What does the video say about pellet implants cannot be removed if levels go too high,?

Pellet implants cannot be removed if levels go too high, making them riskier than gels or patches for women prone to androgenic hair loss.

What does the video say about female testosterone reference ranges vary significantly between labs?

Female testosterone reference ranges vary significantly between labs and are not well standardized, so a result listed as 'normal' does not guarantee it is appropriate for that individual.

What does the video say about hair shedding typically lags a hormonal trigger by 2 to?

Hair shedding typically lags a hormonal trigger by 2 to 4 months, meaning you may not connect the dots between a dose change and hair loss without careful timeline tracking.

Islam et al. (2019, Journal of the American Academy of Dermatology) confirmed exogenous androgen exposure as a recognized cause of female pattern hair loss, validating the creator's core clinical point?

Islam et al. (2019, Journal of the American Academy of Dermatology) confirmed exogenous androgen exposure as a recognized cause of female pattern hair loss, validating the creator's core clinical point.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Not medical advice. This video was made by Dr Breanne Kallonen ND, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.